

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 02-742-E; 400/130)

In the Application of:)
McSwiggen et al.)
Serial No.: 10/664,668) Examiner: TBA
Filing Date: September 18, 2003) Group Art Unit: 1635
For: RNA Interference of Mediated Inhibition) Confirmation No. 5711
Of Vascular Endothelial Growth Factor)
And Vascular Endothelial Growth Factor)
Receptor Gene Expression Using Short)
Interfering Nucleic Acid (siNA))

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Third Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO/SB/08B form.

Portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. However, if the Commissioner determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, he is authorized to charge any such fee to our Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: May 31, 2007

By: /Christopher P. Singer/
Christopher P. Singer
Registration No. 48,701

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002